Many conventional chemotherapeutic drugs, as well as DNA for cancer gene therapy, require efficient access to the cells' interior to be effective. The cell membrane is a formidable barrier to many of these drugs, including therapeutic DNA constructs. Electropermeabilization (EP, often used synonymously with "electroporation") has become a useful method to temporarily increase the permeability of the cell membrane, allowing a broad variety of molecules efficient access to the cell interior. EP is achieved by the application of short electrical pulses of relatively high local field strength to the target tissue of choice. In cancer therapy, EP can be applied in vivo directly to the tumor to be treated, in order to enhance intracellular uptake of drugs or DNA. Alternatively, EP can be used to deliver DNA into cells of healthy tissue to achieve longer-lasting expression of cancer-suppressing genes. In addition, EP has been used in ex vivo therapeutic approaches for the transfection of a variety of cells in suspension. In this paper, we communicate results related to the development of a treatment for squamous cell carcinomas of the head and neck, using electropermeabilization to deliver the drug bleomycin in vivo directly into the tumor cells. This drug, which is not particularly effective as a conventional therapeutic, becomes highly potent when the intracellular concentration is enhanced by EP treatment. In animal model experiments we found a drug dose of 1 U/cm 3 tumor tissue (delivered in 0.25 mL of an aqueous solution/cm 3 tumor tissue) and an electrical field strength of 750 V/cm or higher to be optimal for the treatment of human squamous cell tumors grown subcutaneously in mice. Within 24-48 hours, the majority of tumor cells are rapidly destroyed by this bleomycin-electroporation therapy (B-EPT). This raises the concern that healthy tissue may be similarly affected. In studies with large animals we showed that normal muscle and skin tissue, normal tissue surrounding major blood vessels and nerves, as well as healthy blood vessels and nerves themselves, are much less affected than tumor tissue. Normal tissues did show acute, focal, and transitory effects after treatment, but these effects are relatively minor under standard treatment conditions. The severity of these effects increases with the number of electric pulse cycles and applied voltage.
Introduction
The effectiveness of potentially powerful cancer therapeutics is often limited by their inability to efficiently penetrate the cell membrane. This is true for chemotherapeutic drug molecules that act intracellularly, as well as for DNA, the drug-equivalent in cancer gene therapy. Methods that enhance cellular uptake of drugs and DNA may therefore lead to more effective treatments of cancer. Approaches taken to achieve that goal include the chemical modification of drugs (1), specific drug formulations (2), and the design of drug delivery devices (3, 4) . Most anticancer drugs are delivered systemically. However, systemic drug administration is most often limited by the drug's toxicity. To circumvent that obstacle, attempts have been made to apply high concentrations of drugs locally. These approaches include the prolonged exposure of tumors to high concentrations of drugs formulated in a collagen matrix that is injected into the tumor (5), or local activation of low-toxicity precursor drugs used in photodynamic therapy (6) or "suicide" gene therapies (7) . An attractive approach to enhance local drug effectiveness is to physically change cell membrane permeability for a period of time sufficient to allow therapeutic quantities of the drug to enter and remain in the cell. This can be achieved with electropermeabilization, frequently used synonymously with the term electroporation (8, 9) . Electropermeabilization renders the cell membrane temporarily permeable by inducing the formation of aqueous pores across the lipid bi-layer (10), or by other disturbances of the membrane structure (11). Electropermeabilization is achieved by applying electrical pulses of short duration (micro to milliseconds) and high field strength (100-1500 V/cm) directly to the tissue or cell suspension to be treated. Thus, electropermeabilization may be used for in vivo as well as ex vivo therapies (12).
Electroporation therapy (EPT) involves the delivery of therapeutic substances across membrane barriers with the help of electrical fields. Okino and Mohri (13) in 1987 were the first to use EP for treating tumors in animals. Four years later, Mir and colleagues reported the first treatment of local tumors in human patients. Since then, encouraging pre-clinical and clinical results have emerged from the use of this methodology to treat various types of malignant tumors with different anticancer drugs (8, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . Among the drugs tested in combination with electroporation, bleomycin has shown the highest cytotoxicity enhancement, up to 5000fold over the toxicity measured by tumor cell killing in the absence of electroporation (24, 25) . Bleomycin electroporation therapy (B-EPT) involves intratumoral or intravenous injection of the drug, followed by application of the pulsed electrical field, preferably administered by the insertion of needle array electrodes into the tumor tissue. This treatment rapidly destroys tumor cells within 24-48 hours (26, 27) .
While the lethal effect of B-EPT on tumor cells has been widely documented, much less is known about the effect of this treatment on healthy tissues (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Understanding the effects of B-EPT on healthy tissue will be important for the safe and effective clinical application of this treatment modality as its frequency of use increases.
In this paper we describe the optimization of B-EPT treatment parameters in an animal model for human squamous cell carcinomas of the head and neck, including the effect of bleomycin dose and concentration, and the electrical field strength applied to the tumor. We also report results regarding the effect of B-EPT on healthy tissues that are particularly relevant in treating tumors in the head and neck area. Finally, we present results of recent Phase II clinical studies which demonstrate the safety and usefulness of this new technology in cancer therapy.
Materials and Methods
The procedures used in the animal studies described in this paper conform to those described in the Guide for Care and Use of Laboratory Animals and the Vivarium Standard Operating Procedures of the test facilities.
Optimization of Bleomycin-Electroporation Therapy (B-EPT) treatment in mice
Six week old BALB/cA nu/nu mice, equal numbers from both sexes, were purchased from Harlan Sprague Dawley, Inc., Indianapolis, IN. HEp-2 cells (ATCC CCL-23, passage No. 350) were grown in RPMI-1640 medium (GIBCO, Life Technologies, Inc.) supplemented with 10% FBS (GIBCO) in a 5% CO 2 -air atmosphere at 37 ºC. The HEp-2 cell line is derived from a human larynx epidermoid carcinoma. Mice subsequently treated with the 1.0 cm electrode array were injected with 5 million exponentially growing HEp-2 cells in the right flank and tumors were allowed to grow to an average size of 85 mm 3 . Each mouse subsequently treated with a 0.5 cm electrode array was surgically implanted with two pieces of stock tumor of about 2 mm 3 each. Stock tumors were grown in the same strain of mice injected with 6 million HEp-2 cells. Stock tumors were harvested, cut into pieces of about 2 mm 3 each and briefly stored in RPMI-1640 medium with antibiotics before implantation. The implanted tumors were allowed to grow to a volume of 30-65 mm 3 . Tumors seeded either by cell injection or tumor fragments, respectively, did not show any observable differences. The mice were weighed and randomly divided into different control and treatment groups (5 to 10 animals per group). The tumor size was measured using calipers and the tumor volume was calculated using the formula [(π/6) × a × b 2 ] where a and b are the length and width of the tumor in mm. Bleomycin (Mead Johnson, Evansville, IN) was dissolved in sterile phosphate buffered saline (PBS) (Sigma, St. Louis, MO) at 4 U/mL and diluted with PBS as necessary. Prior to B-EPT treatment, the animals were anesthetized by isoflurane inhalation (Ohmeda Caribe, Inc., Guyama, Puerto Rico).
Bleomycin solution was injected intratumorally using a sterile syringe with a 30 gauge needle and a "fanning" technique (37). The volume and concentration of the bleomycin solution injected is given in the Results section for individual experiments. Ten minutes ± 1 minute later, a 6-needle array electrode (Genetronics, Inc., San Diego, CA) was inserted into the tissue in such a way that all six needles surrounded the tumor and the needle tips penetrated at least 1 mm deeper than the root of the tumor. The 6-needle array electrode consisted of six 22-gauge, 1 cm long stainless steel needles with sharp tips, arranged equidistantly spaced around a circle of 1 cm diameter (22).
Electroporation treatment consisted of one pulse cycle delivered by the MedPulser ® device (Genetronics, Inc.) modified to allow selection of the voltage to be delivered. One pulse cycle includes six square wave pulses of 100 µsec each, delivered at 4 Hz, with changing polarity and field orientation (22). The applied voltage was one of the experimental variables and is described in the Results section for individual experiments. Tumor volumes were determined frequently (every four days, on average) for up to 67 days following the B-EPT treatment. Tumor response was categorized on day 60 after treatment as complete response (CR), partial response (PR), objective response (OR), no response (NR), or progressive disease (PD) (38). Control animals were euthanized when tumor burden became excessive. Histological analysis was performed on representative tissue samples of tumors or treatment sites, respectively, of animals randomly selected from all control or treated groups, to confirm absence or presence of malignant cells.
Effect of B-EPT on normal porcine skin and muscle
Ten male and female Yorkshire pigs weighing 25-40 Kg (Pine View Farms, Valley City, OH) were anesthetized by intramuscular injection of Acepromazine (0.55 mg/Kg) mixed with Ketamine (16.7 mg/Kg), followed by 8-10 mL Pentathal (25.0 mg/mL) administered through the ear vein. The animals were intubated and anesthesia was maintained during the following procedure with 1.0-1.5% halothane in oxygen. Blood and urine samples were collected before and after treatment and vital signs were monitored throughout the procedure, including heart activity by EKG. Eighteen treatment sites marked with tattoo ink at the upper hind and fore legs were used on each animal. Half of the animals were injected with bleomycin dissolved in saline (4 U/mL), the other half received saline injection only. Where applicable, animals received electroporation pulses at the injection sites 5 minutes after injection. At two of the eighteen injection sites per animal, 5 mL each of lidocaine (0.5%)-epinephrine (1:200,000) (Abbott Laboratories, Abbott Park, IL) was injected prior to treatment around the treatment sites. The skin and muscle tissue of all treatment sites was slowly injected with saline or bleomycin solution, respectively. The injection volumes were 0.13, 0.19, or 0.35 mL depending on whether the site was to be treated with electrode arrays of 0.5, 1.0 or 1.35 cm diameter. The injection volumes were calculated as 25% of the tissue volume encompassed by the electrode arrays, i.e., the cylindrical plug of tissue defined by the diameter of the specific needle array and the 1 cm depth of needle insertion into the tissue. For example, a 1 cm diameter electrode array inserted to a depth of 1 cm corresponds to a volume of ~0.76 cm 3 of treated tissue and an injection volume of 0.19 mL. After insertion of the electrode array, centered around the site of drug or saline injection, electroporation pulses were delivered with a MedPulser ® device (Genetronics, Inc.) to all treatment sites, except for three sites per animal that served as no-electroporation controls. One pulse cycle (see above) was delivered to each site, with standard applied voltages of 560, 1130, and 1500 V, respectively, for electrode arrays with diameters of 0.5, 1.0, and 1.35 cm. The standard applied voltages were calculated to yield approximately equal electrical field strengths (V/cm) in the centers of the different electrode arrays (8, 22) . On days 1, 5, 10, 20, and 40 after treatment, one animal each treated with bleomycin or saline, respectively, was sacrificed by injecting an overdose of pentobarbital (200 mg/Kg). Blood and urine samples were collected for analysis before sacrifice. After euthanasia, approximately 1.2 cm deep tissue plugs of ~0.7, 1.3, and 1.8 cm diameter, respectively, corresponding to prior treatment with 0.5, 1.0, or 1.35 cm diameter electrode arrays, were resected from all treatment sites, fixed in 10% formalin, processed by routine histology techniques to yield hematoxilin-eosin stained tissue slices, and examined independently by two veterinary pathologists for type and severity of histological changes. Types of changes evaluated included necrosis, inflammation, hemorrhage and fibrosis of muscle, and epidermal damage and subcutaneous inflammation of skin. The severity of changes was graded on a zero to five scale, corresponding to the designations: nonexistent, minimal, mild, moderate, severe, and very severe. Comparative and descriptive statistics were used to evaluate the effects of EPT in the presence and absence of bleomycin in relation to various treatment parameters, including the presence or absence of lidocaine/epinephrine, the number of electrical pulse cycles, applied voltage, and the electrode array diameter.
Effect of B-EPT on major arteries and nerves in dogs
This study was conducted in two parts involving two dogs each. In the first part, two female Beagle dogs (~18 months old, 8 and 9.5 Kg, Marshall Farms USA, North Rose, NY) were anesthetized (1-5% isoflurane in pure oxygen), intubated, and monitored for main physiological functions throughout the procedure. Sequentially, each carotid sheath and femoral artery was surgically exposed, and treated. One unit of bleomycin (4 U/mL in saline) was injected into approximately 1.0 cm 3 of tissue surrounding the sheath or artery, respectively. Atropine (0.01-0.02 mg/Kg) and then Succinylchloride (0.5 mg/Kg), a neuromuscular blocker, were administered intravenously. Five minutes after injection of bleomycin, a 6-needle array electrode of 1.0 cm diameter, as described above, was inserted into the tissue to a depth of 1 cm. In the first dog, the needles were placed directly around, i.e., spanning, the left carotid sheath; adjacent to the right carotid sheath; and through, i.e., piercing, the left femoral artery (Figure 1 ). The right femoral artery was injected with bleomycin, but did not receive the electroporation treatment. In the second dog, the electroporation needles were placed through the left carotid artery, adjacent to the right femoral artery, and spanning the left femoral artery. The tissue around the right carotid sheath was injected with bleomycin, but was not electroporated. Each site subject to electroporation received three pulse cycles instead of the standard one cycle, delivered by a MedPulser ® device (Genetronics, Inc.) using standard pulse conditions described in the preceding section. Treatment sites were sutured closed, the animals were recovered, and monitored for seven days. On day 7 both animals were euthanized, the tissues of the treatment sites were collected, fixed in 10% formalin, and prepared for histopathological evaluation by standard histological methods. Serum chemistry, hematology, and urine tests were performed prior to treatment and prior to euthanasia. The second part of this study was performed with two 5-6 months old male Beagle dogs (Marshall Farms USA) treated as described in the first part of this study, except that bleomycin was injected into the arterial wall, as well as injected into the surrounding tissue. The animals were treated, and tests were performed as described for the first group, except that both animals were sacrificed three days after treatment.
Clinical Studies
Three separate clinical studies sponsored by Genetronics, Inc., and reported here included a total of 62 patients with squamous cell carcinoma of the head and neck (SCCHN). All three studies were Phase II, open-label, multi-center, non-randomized studies, and are designated North America I, North America II and Europe (20).
North America I: The purpose of this study was to evaluate over 12 weeks the response rate of patients with SCCHN, treated with intratumoral bleomycin and electroporation therapy (B-EPT) in lesions with disease progression, after intratumoral bleomycin treatment without electroporation was judged ineffective. The study population included patients with biopsy-confirmed SCCHN that was refractory to standard therapy, or that recurred after standard therapy. Only patients who were not suitable for, or not willing to undergo salvage therapy, were included. All patients received an initial treatment of intratumoral (i.t.) injection of bleomycin. One additional treatment with i.t. bleomycin was at the physician's discretion for patients evaluated to have a tumor response of 'no change' or 'partial response.' Patients with tumor evaluations of progressive disease after one or two i.t. injections of bleomycin were crossed over to B-EPT treatment. Bleomycin was administered as an i.t. injection of an aqueous solution of 4 U/mL at a dose of 1 U/cm 3 of tumor at the time of treatment (0.25 mL for each cm 3 of tumor tissue). Patients were evaluated prior to treatment, within 14 days of initiation of treatment, and at 4 week intervals after treatment for 12 weeks. Patients exhibiting complete response were to be followed at 3 month intervals until manifestation of 'progressive disease,' if any. This study included 25 patients ranging in age from 47-89 years (median = 63 years), 88% male and 12% female. Tumor response was determined by objective measurement of the target lesions' bi-dimensional size (i.e., the product of the longest diameter and its perpendicular dimension, applied to the widest portion of the target lesion), either by direct measurement of the tumor or from measurements of CT/MRI scans. Lesion responses were defined according to the following definitions: 'complete response' (CR) required the disappearance of treated tumor, determined by two evaluations not less than 4 weeks apart; 'partial response' (PR) required a 50% or greater decrease in the bi-dimensional size of the lesion by two evaluations not less than 4 weeks apart.
North America II. This study also included 25 patients (51-85 years of age; median = 69 years; 80% male and 20% female). All other study design parameters were the same as in North America I, except that all enrolled patients received B-EPT treatment without a preceding bleomycin-only treatment.
Europe. This study was conducted in France and involved 12 patients (50-78 years of age ; median = 67 years; 58% male and 42% female). The subject population included patients with biopsy confirmed SCCHN who had failed conventional curative therapy, including surgery and/ or radiation therapy. All other study design parameters were the same as for North America II. The purpose of this study was to evaluate over 12 weeks the objective tumor response to B-EPT treatment of head and neck carcinomas in patients who have failed conventional therapy. In addition, the systemic and local toxicity/morbidity safety profile of B-EPT and the operational performance of the MedPulser ® were to be determined.
Results and Discussion

Optimization of treatment parameters in an animal model
The most important B-EPT treatment parameters include drug dose, drug concentration and applied voltage. Our objective was to maximize therapeutic efficacy as measured by the change in tumor size, while keeping detrimental side effects of the treatment to a minimum. We also aimed to establish the lowest values of drug dose and applied voltage that still yield maximal tumor reduction. Since our main clinical interest was the treatment of squamous cell carcinoma (SCC) of the head and neck, we chose as our test system nude mice with subcutaneously implanted tumors derived from a human larynx epidermoid cancer cell line, HEp-2. The dependence of the tumor response on the bleomycin dose for two different electrode arrays of 1.0 cm and 0.5 cm diameter, respectively, is shown in Figure 2 . For both electrode arrays the tumor response determined 60 days after treatment was optimal, or close to optimal, at a bleomycin dose of 1 U/cm 3 tumor tissue (applied as 0.25 mL of a 4 U/mL bleomycin solution/cm 3 tumor tissue). As the bleomycin concentration increased from 0.5 to 4 U/mL the percentage of animals with complete tumor response increased to 90% and 100% respectively, whereas the percentage of animals with partial tumor response or progressive disease declined to 10% and 0%, respectively. From these results we conclude that under standard electroporation conditions (applied voltages of 1130 V and 560 V for 1.0 cm and 0.5 cm electrode arrays, respectively, and the pulse characteristics described in the Materials and Methods section), 1 U/cm 3 tumor tissue is the minimal bleomycin dose for this type of tumor that results in maximal tumor response. All control animals that did not receive bleomycin, electroporation, or any treatment at all, showed progressive disease.
The effect of the applied voltage on tumor response is summarized in Figure 3 . Increasing the voltage from 409 V to 1130 V for the 1.0 cm electrode array, and from 203 V to 560 V for the 0.5 cm electrode array, respectively, increases the percentage of complete tumor response, while decreasing the fraction of partial response or progressive disease response. The applied voltages we have adopted as standard voltages delivered by the MedPulser ® device for the 1.0 cm and 0.5 cm diameter electrode arrays, namely 1130 V and 560 V, yield optimal or close to optimal results. The applied voltages correspond to a nominal electrical field strength of 1287 V/cm and 1276 V/cm, respectively (39). However, it should be noted that the needle electrode arrays generate quite inhomogeneous electrical fields (Figure 4) . We have calculated that for both the 1.0 cm and 0.5 cm electrode arrays the minimum actual field strength in the centers of the needle arrays is about 750 V when the standard voltage is applied to each electrode array. On the other hand, the actual field strength in the proximity of the needle electrodes is substantially higher than the nominal field strength. The results shown in Figure 3 indicate that the standard voltages delivered by the MedPulser ® device (1130 V for the 1.0 cm electrode array, and 560 V for the 0.5 cm electrode array) are close to the minimum voltages required to achieve 90% or higher complete tumor response rates in this model system. The next lower voltages tested (800 V and 397 V, respectively) show a significantly lower positive response rate. In a separate experiment, similar to the experiments described above, we investigated the effect of drug concentration, i.e., drug injection volume, on the efficacy of B-EPT. We varied injection volumes from 0.1 to 1.0 mL per cm 3 tumor for three different constant doses of bleomycin (1.0, 0.5, and 0.25 U/cm 3 tumor). The results did not indicate a consistent correlation between drug injection volume and treatment efficacy (40). We conclude from the lack of a clear result that in this model system (small tumors in mice) it is experimentally very difficult to reproducibly and homogeneously inject tumors with a defined volume of drug solution. The significance of the drug injection volume will have to be studied further under better suitable conditions, e.g., in a large animal/large tumor model, or in clinical studies.
In conclusion, the results of the optimization of bleomycin dose and applied voltages in the experiments described here firmly establish a dose of one unit of bleomycin per cm 3 tumor, and an applied voltage of 1130 V for the 1.0 cm electrode array, and 560 V for the 0.5 cm electrode array as treatment parameters that yield maximal efficacy at the mildest treatment conditions in this animal model. These conditions were also used for the treatment of SCCHN in patients. To what extent these treatment parameters are truly optimal in humans can only be established in a voluminous clinical study. However, concluding from the clinical results available so far, the treatment parameters established here for a specific SCC model seem to extrapolate reasonably well to the treatment of SCC of the head and neck in humans. Other types of tumors each may require separate treatment optimization. For example, we have found in a rat rhabdomyosarcoma model that doses of bleomycin lower than 1 U/cm 3 tumor may be sufficient to obtain maximum efficacy (Nanda and Rabussay, unpublished results) .
Effect of B-EPT on normal tissue.
While the efficacy of B-EPT in eliminating tumor tissue has been well documented in animal models as well as in patients (8, 9, 14, 18, 20, 21, 23) , the effect of this treatment on normal tissue has received much less attention (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Understanding the effect of B-EPT on normal tissue is important for proper use of this methodology in clinical practice, including the treatment of tumor margins, the treatment of tumors close to essential anatomical structures such as major vessels and nerves, and the healing of wounds generated by the destruction of the tumor.
Our observations during experiments in rodents, as well as early clinical observations, suggest that tumor tissue is more severely affected by B-EPT than normal tissue. Similar conclusions were drawn by others from their experiments in rodents (28-31). Because of our interest in clinical applications of B-EPT, we found it important to conduct a systematic study of the effects of this treatment on normal tissue in relevant large animal models, with the ultimate goal of determining conditions that will identify and allow to minimize undesirable effects on normal tissue in patients. We chose porcine skin and muscle, and major arteries and the vagus nerve of dogs as model tissues, all of which are established models for subsequent human studies. We studied the effects of standard B-EPT conditions as well as exaggerated conditions to determine the effects generated under "worst case" conditions.
Effect of B-EPT on normal porcine skin and muscle.
The standard B-EPT treatment we have used in recent stud- Saline (upper panel) or bleomycin (1 U/cm 3 tissue; administered as a 4 U/mL solution at 0.25 mL/cm 3 tissue) (lower panel) was injected into skin and muscle tissue of pigs, followed by EPT with 6-needle array electrodes at the corresponding standard voltages. Different numbers of electric pulse cycles were applied as indicated. At different times after treatment, biopsies were taken from the treated areas and processed for histological evaluation. The histological specimens were evaluated by a veterinary pathologist, and the severity of histological change was scored on the scale of 0 to 5, with 0 representing no change, and 5 indicating severe change. Note that the standard treatment consists of one pulse cycle, which results in minimal to mild changes in the absence of bleomycin during the first ten days, and no detectable changes thereafter.
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In the presence of bleomycin, one pulse cycle leads to mild to moderate changes during the first 10 days after treatment, but only minimal changes are detectable 40 days after treatment.
ies for treating solid tumors in humans (20) includes injection of lidocaine-epinephrine into the tissue surrounding the tumor, intratumoral injection of bleomycin dissolved in saline (4 U/mL; 25% of the tumor volume), insertion of a 6-needle array electrode of 1.0 cm diameter into the tumor, and delivering one cycle of electrical pulses (22) . In addition to applying these standard conditions in this study, we have explored harsher conditions that are not expected to be used clinically, but are likely to provide information about the safety margin in relation to the standard treatment conditions. Study parameters included the presence or absence of lidocaine-epinephrine and bleomycin, respectively, the number of electrical pulse cycles (1, 2, 4, or 8), enhanced applied voltage, and the diameter of electrode arrays (0.5, 1.0, and 1.35 cm). The effect of these treatment parameters on histological changes was followed over a period of 40 days after treatment. The diameter of the electrode arrays determined the tissue volume subject to treatment, i.e., the volume of the cylinder defined by the array diameter and the depth of needle insertion into the tissue. That volume, in turn, dictated the amount of bleomycin or saline to be injected, i.e., a volume corresponding to 25% of the tissue volume targeted for treatment.
As mentioned in Materials and Methods, different categories of histological changes in the treated tissue were evaluated and the severity of these changes was graded on a scale of 0 to 5, with 0 designating non-existent change and 5 designating severe change. Injection of lidocaine-epinephrine had no effect on any of the results discussed below.
In the following paragraphs we summarize the most pertinent findings.
Muscle necrosis:
The effect of the number of pulse cycles on muscle necrosis is shown in Figure 5 . One pulse cycle in the absence of bleomycin resulted in minimal to mild necrosis which disappeared after ten days. One pulse cycle represents the standard treatment, whereas greater numbers of pulse cycles were applied to explore the potential detriment that can be caused by over-treatment. Higher numbers of pulse cycles caused mild to severe changes during the first five days but no changes were detectable by day 20 and beyond.
In the presence of bleomycin, the changes associated with one pulse cycle were mild to moderate for the first ten days and declined to minimal by day 40; multiple pulse cycles caused more severe damage than seen in the absence of bleomycin and the changes persisted all the way to day 40, albeit at a minimal to mild level. Figure 6 shows the degree of muscle necrosis in relation to the electrode array diameter. The larger the array diameter, the higher the applied voltage has to be in order to achieve the same field strength in the center of the electrode array. However, higher applied voltages mean higher field strengths in the vicinity of the needle electrodes, which implies potentially greater tissue damage. As Figure 6 indicates, the degree of muscle necrosis is indeed roughly proportional to the electrode array diameter. The 1.0 cm array is the most frequently used and causes mild to moderate necrosis during the first ten days, but only minimal histological change by day 40. Note that the bar graphs in Figure 6 represent a severity score related to a particular size electrode array and all tested pulse cycles. The severity score for a 1.0 cm array and one pulse cycle is significantly lower than represented by the bars in Figure 6 . Similar data were collected and similar analyses were performed for other types of histological changes which are not presented in detail here. Brief summaries for the different histological findings follow. Figure 5 . Electroporation was performed with electrode arrays of different diameters, as indicated, using the standard voltage for each array (560 V for 0.5 cm; 1130 V for 1.0 cm; and 1500 V for 1.35 cm). Biopsies were taken and histological evaluation was performed as described in the legend to Figure 5 and in Materials and Methods. Treatment with the 1.0 cm array, the most frequently used size, resulted in moderate necrosis for the first ten days, as averaged over the different numbers of pulse cycles applied. After 20 and 40 days, necrosis was minimal.
cycles, but only minimal levels with one pulse cycle. Before and after day 5, muscle inflammation was generally minimal to mild. Larger array diameters and higher applied voltages increased inflammation severity.
Muscle hemorrhage: Hemorrhage was also most apparent at day 5 but reached only mild levels, even with the harshest treatment conditions. By day 40 hemorrhage was non-existent. Increased numbers of pulse cycles and larger array diameters/higher voltages caused generally more noticeable changes.
Muscle fibrosis: Fibrosis was not detectable on day 1 but peaked on day 5 when it reached modest to severe levels under the harshest conditions. One pulse cycle and 1 cm electrode arrays resulted in no more than mild changes. By day 40, minimal fibrosis was still detectable.
Epidermal damage: This condition was most noticeable on days 1 and 10, but never exceeded mild levels, even under harshest treatment conditions. There was an interesting dip in the degree of damage on day 5. Epidermal damage was barely noticeable by day 40.
Epidermal inflammation: This change was seen sporadically in some tissue samples but there was no apparent correlation with the number of pulse cycles, array diameter, or applied voltage. However, this condition, when observed, did show significantly higher severity in the presence of bleomycin than with saline, but never exceeded modest severity. Epidermal inflammation was most visible on day 1 and decreased with time.
Subcutaneous inflammation:
On days 1, 10, and 20, this condition was most apparent but hardly reached mild levels. On day 5, a clear dip in the noticeable subcutaneous inflammation was observed, and by day 40 this condition was below the minimal level.
To summarize, B-EPT causes acute, focal, and transitory effects which can be significantly affected by the number of electric pulse cycles, electrode array diameter, and applied voltage. EPT in combination with saline results in tissue alterations that are of lesser magnitude and resolve more quickly than the changes caused by EPT with bleomycin. The lack of statistical interaction between pulse cycle number, array diameter, applied voltage, and presence or absence of bleomycin suggests that all of these factors act independently to cause the observed tissue changes, and that they may have additive effects. Reassuringly, all tissue damage observed in this study, even under excessive treatment conditions, healed quickly and fully within the test period of 40 days, with the exception that minimal or sub-minimal levels of necrosis, inflammation, and fibrosis of the muscle, as well as epidermal damage and subcutaneous inflammation were still detectable 40 days post-treatment. However, these remaining traces were of no functional or cosmetic consequence.
Effect of B-EPT on major arteries and nerves in dogs
Surgeons treating head and neck tumors frequently encounter tumors in the vicinity of major blood vessels or nerves. If tumors are close to, or have invaded these vital structures, the tumor may not be resectable. It was therefore important to determine the effect of B-EPT on these structures in order to provide guidance to surgeons for treating tumors as closely as possible to major vessels and nerves while avoiding serious consequences. We conducted this study in two parts. In the first part, we evaluated histological changes visible seven days after injection of bleomycin into tissue closely adjacent to the carotid sheath and the femoral artery. In the second part, we determined histological changes during the acute response phase, three days after bleomycin injection. In addition, bleomycin was not only injected into tissue adjacent to arteries, but also into arterial walls. Although the latter procedure is not intended to be performed in humans, it represents the worst case scenario in terms of potential arterial damage that can be inflicted by B-EPT.
Electroporation caused acute, local, transient vascular spasm without lasting detrimental effects. Heart function was not affected at any time. No changes in behavior or mobility of the animals were apparent, nor changes in hematology and clinical chemistry data. Histopathalogical evaluation of the various tissue samples revealed some localized hemorrhage in the treatment area, most likely due to mechanical damage from needle insertions. Also, some degeneration of skeletal muscle fibers was visible. However, no significant changes in vessels or nerves was apparent except when bleomycin was directly injected into the vessel wall, followed by electroporation. In the latter case, the changes included necrosis and loss of medial smooth muscle cells, adventitial fibrocytes, and intimal endothelial cells. This local cytotoxicity frequently resulted in only extracellular matrix and elastic fibers remaining. Only slight atonal degeneration was observed in the vagus nerves proximal to these same carotid arteries. By contrast, the segments of a femoral artery subjected to direct injection of bleomycin, but not to electroporation, exhibited only mild arterial change, and the carotid artery treated analogously remained normal. Also, injection of bleomycin about 5 mm away from either the carotid or femoral artery, followed by electroporation, caused no morphological changes. It is remarkable that even in the worst case scenarios that are not intended and extremely unlikely to occur in the treatment of patients, the animals did not show any signs of clinical impairment during the relatively short observation period of three days. The long-term implications of the major histomorphological changes remain to be determined. We conclude that, except in the extreme case of bleomycin injection into the arterial wall and subsequent electroporation, it appears that healthy tissue close to major arteries and nerves, as well as the vessels and nerves themselves, are not significantly affected by treating the tissue surrounding these structures. However, these results must be applied with caution to the treatment of patients since tissue that appears healthy may actually have been invaded by cancer cells and we have no experience as to how cancer-infiltrated tissue responds to B-EPT.
Clinical Results
The first combined treatments of patients with an anticancer drug and electroporation was reported in 1991 (15). Since then, we are aware of about 160 patients that have been treated by this method (8, 14, 41, 43) , but only about one-half of the cases have been reported in journal articles in the medical-scientific literature. Different variations of the method have been explored, including intravenous versus intratumoral drug administration, bleomycin or cisplatin as anticancer drugs, plate versus needle electrodes, and a variety of different electrical pulse parameters (8, 9, 14) . The majority of cancers treated were cancers of the skin, including basal cell carcinomas, melanomas, and squamous cell carcinomas (15-17, 44, 45) . The second largest group of patients treated suffered from squamous cell carcinomas of the head and neck (18, 20, 21, 46, 47) . Recent head and neck cancer clinical studies, the most comprehensive studies of their kind to date, were initiated by Genetronics, Inc., and included an FDAauthorized Phase II study in the U.S. and Canada, and clinical trials in France authorized by regional health authorities.
The results of these studies, an earlier version of which has been presented at the 1999 meeting of the American Society of Clinical Oncology (20) are summarized in Table I . The study design and treatment procedures are described in Materials and Methods. The study designated North America I was designed as a cross-over study where patients initially received intratumoral bleomycin but no electroporation. Patients with progressive disease evaluations after one or two bleomycin injections were then treated with bleomycin and electroporation. Only one of 37 evaluable tumors (3%) in 25 patients treated with bleomycin only, showed a partial tumor response; all others showed no response. Seventeen of these patients were then treated with bleomycin and electroporation, resulting in a 55% objective tumor response, including a 30% complete tumor response. These results clearly demonstrate that bleomycin treatment by itself has essentially no therapeutic effect, whereas bleomycin injection followed by intracellular delivery of the drug with electroporation yields a surprisingly high percentage of objective and complete responses. The North America II study included 25 patients with 31 evaluable tumors that were treated once with bleomycin and electroporation. The objective response was similar as in the North America I study (58%) but, the com-plete response rate was 19% rather than 30%. The European study (France) with 12 patients and 18 evaluable tumors resulted in response rates very similar to those obtained in North America I, namely 56% objective and 28% complete tumor response. The results of these studies indicate that BEPT treatment is a safe therapeutic approach that evokes a significant positive tumor response in patients who are left with very limited treatment options. Other demonstrated or potential benefits of B-EPT treatment include its tissue-sparing and organ-preserving character compared to surgical intervention or radiation, and reduced or absent side effects such as nausea, alopecia, and bone marrow destruction common in conventional chemotherapy. In addition, the procedure can be performed on an outpatient basis and is more cost effective for both the patient and the health care provider (9, 18, 21, 47) . Bleomycin-Electroporation treatment has also shown promise to be a safe and effective treatment modality for other solid tumors in both animal studies (8, 9) and in limited clinical trials (8, (41) (42) (43) . Inherent limitations of EPT include muscle contractions elicited by the electrical pulses, the requirement for accessibility of the tumor to the treatment, and the limitation of treatment efficacy to local/regional tumors. Despite these limitations, B-EPT promises to become applicable and useful for the treatment of many different solid tumors as instrumentation and clinical techniques continue to evolve. Rabussay et al. Table I Response of squamous cell carcinomas of the head and neck to treatment with bleomycin or bleomycin with EPT. The results of three different clinical studies in North America and Europe are shown. In the North America I study, patients were first treated with bleomycin only. If the tumor(s) progressed, these patients were crossed over to treatment with bleomycin and EPT. CR = complete response; PR = partial response; OR = objective response (CR + PR).
